Janux Therapeutics (JANX) Cash from Operations (2020 - 2026)
Janux Therapeutics' (JANX) quarterly Cash from Operations came in at 12337000.0 in Q1 2026, up 27.53% year-on-year from 9673671.78 in Q1 2025, and up 56.78% on a QoQ basis from 28542000.0 in Q4 2025.
Janux Therapeutics (JANX) Cash from Operations (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of Cash from Operations data on file, last reported at 12337000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations rose 27.53% year-over-year to 12337000.0 in Q1 2026; TTM through Mar 2026 was 77548000.0, a 68.58% decrease from a year earlier, with the FY2025 full-year figure at 82235000.0, down 87.69% from the prior year.
- Cash from Operations for Q1 2026 stood at 12337000.0, up from 28542000.0 in the prior quarter.
- Over the last five years, Cash from Operations for JANX reached as high as 2231000.0 in Q3 2024 and fell as low as 28542000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 13640176.47 across 5 years, with a median of 12856000.0 in 2025.
- Across the five-year window, Cash from Operations soared 80.95% in 2024 and slumped 476.24% in 2025, its largest moves.
- Year by year, Cash from Operations stood at 11913000.0 in 2022, then gained by 16.89% to 9901000.0 in 2023, then plunged by 68.92% to 16725000.0 in 2024, then plunged by 70.65% to 28542000.0 in 2025, then surged by 56.78% to 12337000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 12337000.0 in Q1 2026, 28542000.0 in Q4 2025, and 12856000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Janux Therapeutics | 985.11 Mn | 985.11 Mn | - | -12.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.34 Mn |
| Mar 31, 2026 | -12.34 Mn |
| Dec 31, 2025 | -28.54 Mn |
| Dec 31, 2025 | -28.54 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Jun 30, 2025 | -23.81 Mn |
| Jun 30, 2025 | -23.81 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | -16.73 Mn |
| Dec 31, 2024 | -16.73 Mn |
| Sep 30, 2024 | -2.23 Mn |
| Sep 30, 2024 | -2.23 Mn |
| Jun 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -10.02 Mn |
| Mar 31, 2024 | -14.84 Mn |
| Mar 31, 2024 | -14.84 Mn |
| Dec 31, 2023 | -9.90 Mn |
| Dec 31, 2023 | -9.90 Mn |